| |
|
|
|
|
|
This test is a qualitative immunoassay for detecting antibodies specific to the Hepatitis C Antigen found in serum, plasma samples.
|
Company:
Date:
March 15, 2009
|
|
|
|
|
|
|
|
|
|
The Aware™ HIV-1/2 BSP test is a single-use, qualitative, visually read, in vitro immunoassay for the detection of antibodies to Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) and Type 2 (HIV-2) in human whole-blood (obtained by finger-stick or venous draw) serum or plasma specimens. The Aware™ HIV-1/2 BSP test is intended for use as a point-of-care aid in the clinical diagnosis of HIV infection. It can be used as a component of a multi-test rapid HIV testing algorithm in conjunction with other approved HIV antibody assays.
|
Company:
Date:
December 18, 2008
|
|
|
|
|
|
|
|
|
|
The Aware™ HIV-1/2 OMT (oral fluid) test and its over-the-counter version, Aware™ Oral, is a single-use, qualitative, visually read, in vitro immunoassay for the detection of antibodies to HIV Type 1 (HIV-1) and Type 2 (HIV-2) in human oral fluid specimens (oral mucosal transudate). The test is intended for use as a point-of-care aid in the clinical diagnosis of HIV infection. It can be used as a component of a multi-test rapid algorithm in conjunction with other approved HIV-antibody assays.
|
Company:
Date:
December 18, 2008
|
|
|
|
|
|
|
|
|
|
The Aware™ HIV-1/2 U (urine) test is a single-use, qualitative, visually read, in vitro immunoassay for the detection of antibodies to human immunodeficiency virus Type 1 (HIV-1) and Type 2 (HIV-2) in human urine specimens. The Aware™ HIV-1/2 U test is intended for use as a diagnostic aid in the clinical diagnosis of HIV infection. It can be used as a component of a multitest rapid HIV testing algorithm in conjunction with other approved HIV antibody assays.
|
Company:
Date:
December 18, 2008
|
|
|
|
|
|
|
|
|
|
DoubleCheckGold™ Ultra HIV 1&2 test is a single use rapid immunoassay based on immunochromatography. It employs unique reagents for the quick and reliable detection of antibodies for HIV-1 and HIV-2 in human serum, plasma and whole blood without instrumentation and without the need for an applicator
|
Company:
Date:
March 15, 2009
|
|
|
|
|
|
|
|
|
|
Genie II HIV-1/HIV-2 is a rapid EIA test for specific detection and differentiation of anti-HIV-1 and anti-HIV-2 antibodies in human serum or plasma
|
Company:
Date:
March 15, 2009
|
|
|
|
|
|
|
|
|
|
The ImmunoComb® is a solid-phase EIA. The solid phase is a plastic comb with 12 teeth, sensitized at different spots with reactive materials and an internal control. All the reagents for the test are saled with foil in a developing plate, containing 6 rows of 12 premixed, prefilled wells. The specimens are deposited in the wells of the first row of the developing plate.
|
Company:
Date:
March 15, 2009
|
|
|
|
|
|
|
|
|
|
Explanation of the test
HIV (Human Immunodeficiency Virus) is recognized as the
etiologic agent of Acquired Immune Deficiency Syndrome
(AIDS). The virus is transmitted by sexual contact, exposure to
infected blood, certain body fluids or tissues, and from mother to
fetus or child during the perinatal period. This clinical diagnostic
issues related to HIV are the detection of HIV 1&2 antibodies in
human plasma or serum by immunoassay. Among the existing
immunological method, the ELISA format and
immunochromatographic format (rapid) to detect antibody of
HIV are available. Synthetic peptides and
|
Company:
Date:
March 15, 2009
|
|
|
|
|
|
|
|
|
|
MiraCare HIV is used in point-of-care (POC) and over-the-counter (OTC) testing for the detection of antibodies to HIV-1 and HIV-2. Each test kit contains all of the necessary components to perform the test in any type of testing environment. MiraCare HIV is approved for sale in the European Union (CE Mark) for POC and laboratory use and is available in select Asian markets as an OTC product.
|
Company:
Date:
March 15, 2009
|
|
|
|
|
|
|
|
|
|
Multispot HIV-1/HIV-2 is a rapid indirect EIA using recombinant and peptide antigens for simultaneous detection and differentiation of anti-HIV-1 and anti-HIV-2 antibodies in human serum or plasma.
|
Company:
Date:
March 15, 2009
|
|
|
|
|
|